Quest Diagnostics
557 hedge funds and large institutions have $9.29B invested in Quest Diagnostics in 2016 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 191 increasing their positions, 196 reducing their positions, and 40 closing their positions.
63% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 40
34% more call options, than puts
Call options by funds: $51M | Put options by funds: $37.9M
4% more funds holding
Funds holding: 535 → 557 (+22)
1.27% more ownership
Funds ownership: 92.58% → 93.85% (+1.3%)
1% less capital invested
Capital invested by funds: $9.43B → $9.29B (-$134M)
3% less repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 196
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal London Asset Management
United Kingdom
|
+$166M |
| 2 |
HM
HealthCor Management
New York
|
+$88.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$61.7M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$187M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$48M |
| 3 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$27M |
| 4 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$19.1M |
| 5 |
DSA
Davis Selected Advisers
Tucson,
Arizona
|
-$18.5M |
DGX Hedge Fund Activity: Q1 2016 in Review
557 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q1 2016, worth a combined $9.29B — down 1.4% from $9.43B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new DGX positions and 40 closed out — a net gain of 25 holders — while 191 added to existing stakes and 196 trimmed.
The largest buyer was Royal London Asset Management, adding an estimated $166M. The largest seller was Boston Partners, exiting entirely with an estimated $187M sold.
- 557 institutional investors held Quest Diagnostics (DGX) as of Q1 2016, up from 535 in Q4 2015.
- Funds reported $9.29B of Quest Diagnostics stock for Q1 2016, down 1.4% quarter-over-quarter.
- 65 funds opened new Quest Diagnostics positions in Q1 2016 and 40 closed out, a net change of +25 holders.
- The largest Quest Diagnostics buyer in Q1 2016 was Royal London Asset Management, an estimated $166M added.
- The largest Quest Diagnostics seller in Q1 2016 was Boston Partners, an estimated $187M sold.
Based on aggregated 13F filings for Q1 2016.